- Home
- NUWE vs AIDX Comparison
NUWE vs AIDX Comparison
Compare NUWE & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUWE | AIDX |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.0M |
| IPO Year | 2012 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NUWE | AIDX |
|---|---|---|
| Price | $5.45 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 129.2K |
| Earning Date | 11-11-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.48 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,270,000.00 | $2,045,133.00 |
| Revenue This Year | $19.32 | $44.20 |
| Revenue Next Year | $12.01 | $95.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.28 | $0.23 |
| 52 Week High | $222.30 | $18.96 |
Technical Indicators
Market Signals| Indicator | NUWE | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 24.59 |
| Support Level | $3.85 | N/A |
| Resistance Level | $13.14 | $0.69 |
| Average True Range (ATR) | 0.81 | 0.02 |
| MACD | 0.47 | 0.00 |
| Stochastic Oscillator | 78.02 | 1.63 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.